Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Beam Therapeutics Inc (NASDAQ: BEAM) was $23.09 for the day, down -2.12% from the previous closing price of $23.59. In other words, the price has decreased by -$2.12 from its previous closing price. On the day, 1.7 million shares were traded. BEAM stock price reached its highest trading level at $23.54 during the session, while it also had its lowest trading level at $22.54.
Ratios:
Our analysis of BEAM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.75 and its Current Ratio is at 6.75. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On March 10, 2025, Scotiabank Upgraded its rating to Sector Outperform which previously was Sector Perform but kept the price unchanged to $40.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 30 ’25 when FMR LLC sold 48,374 shares for $20.50 per share. The transaction valued at 991,667 led to the insider holds 2,073,665 shares of the business.
Simon Amy sold 876 shares of BEAM for $17,625 on Jul 03 ’25. The Chief Medical Officer now owns 64,864 shares after completing the transaction at $20.12 per share. On Jul 01 ’25, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 374 shares for $16.94 each. As a result, the insider received 6,336 and left with 65,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2386412288 and an Enterprise Value of 1273675264. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.76 while its Price-to-Book (P/B) ratio in mrq is 2.22. Its current Enterprise Value per Revenue stands at 21.132 whereas that against EBITDA is -3.004.
Stock Price History:
The Beta on a monthly basis for BEAM is 2.22, which has changed by -0.078243494 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $35.25, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is 17.85%, while the 200-Day Moving Average is calculated to be 6.76%.
Shares Statistics:
BEAM traded an average of 2.64M shares per day over the past three months and 2651340 shares per day over the past ten days. A total of 100.76M shares are outstanding, with a floating share count of 91.32M. Insiders hold about 9.73% of the company’s shares, while institutions hold 101.29% stake in the company. Shares short for BEAM as of 1756425600 were 25477842 with a Short Ratio of 9.65, compared to 1753920000 on 24615341. Therefore, it implies a Short% of Shares Outstanding of 25477842 and a Short% of Float of 28.299999999999997.
Earnings Estimates
The dynamic stock of Beam Therapeutics Inc (BEAM) is currently attracting attention from 10.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.79 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$3.78 and -$4.92 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$4.39, with 13.0 analysts recommending between -$3.01 and -$5.73.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $25M to a low estimate of $8M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $14.27MFor the next quarter, 10 analysts are estimating revenue of $13.84M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $8M.
A total of 12 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $65.9M, while the lowest revenue estimate was $31.9M, resulting in an average revenue estimate of $45.41M. In the same quarter a year ago, actual revenue was $63.52MBased on 12 analysts’ estimates, the company’s revenue will be $44.9M in the next fiscal year. The high estimate is $110M and the low estimate is $80k.
